Literature DB >> 7704245

p53 immunostaining distinguishes malignant from benign lesions of the gall-bladder.

Y Oohashi1, H Watanabe, Y Ajioka, K Hatakeyama.   

Abstract

The expression of p53 protein was studied in formalin-fixed paraffin-embedded specimens of 41 well-differentiated adenocarcinomas of the gall-bladder, six cases of acute cholecystitis and 23 cases of chronic cholecystitis, using a monoclonal p53 (PAb 1801) antibody and streptavidin-biotin. p53 staining was divided into diffuse, focal or sporadic patterns. The relationship between the p53 Labeling Index (p53 LI) and cellular proliferation was also investigated using monoclonal Ki-67 (MIB1) antibody. Twenty-four of the 41 carcinomas (58.5%) had a diffuse staining pattern with a high p53 LI (47-93%) and 9.8% (4/41) had a focal staining pattern with an intermediate p53 LI (22-34%), with no relation to pT stage, tumor size, histologic type or grade of cytologic atypia. The p53 LI was higher than the Ki-67 LI in these tumors except for one. On the other hand, p53 staining was completely sporadic in the non-neoplastic specimens with a low p53 LI (0.2-2.8%). The p53-positive cells in these specimens were located only within areas of Ki-67-positive cells. In conclusion, p53-protein overexpression occurs as an early event in approximately 70% of well-differentiated adenocarcinomas of the gall-bladder, and this alteration is maintained during progression from intramucosal to invasive carcinoma. p53 immunostaining can distinguish malignant from benign lesions of the gall-bladder.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7704245     DOI: 10.1111/j.1440-1827.1995.tb03380.x

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  10 in total

Review 1.  Pancreaticobiliary maljunction and carcinogenesis to biliary and pancreatic malignancy.

Authors:  Takahiko Funabiki; Toshiki Matsubara; Shuichi Miyakawa; Shin Ishihara
Journal:  Langenbecks Arch Surg       Date:  2008-05-24       Impact factor: 3.445

2.  Expression of cyclooxygenase-2 is associated with p53 accumulation in premalignant and malignant gallbladder lesions.

Authors:  Mateja Legan; Bostjan Luzar; Vera Ferlan Marolt; Andrej Cor
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

3.  Ulcerative colitis with overexpression of p53 preceding overt histological abnormalities of the epithelium.

Authors:  K Matsuda; H Watanabe; Y Ajioka; M Kobayashi; H Saito; M Sasaki; K Yasuda; A Kuwabara; K Nishikura; T Muto
Journal:  J Gastroenterol       Date:  1996-12       Impact factor: 7.527

4.  Correlation of p53 protein expression with apoptotic incidence in colorectal neoplasia.

Authors:  M Kobayashi; H Watanabe; Y Ajioka; M Yoshida; J Hitomi; H Asakura
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

5.  Deregulation of MYC and TP53 through genetic and epigenetic alterations in gallbladder carcinomas.

Authors:  Geraldo Ishak; Mariana Ferreira Leal; Ney Pereira Carneiro Dos Santos; Samia Demachki; Caroline Aquino Moreira Nunes; Barbara do Nascimento Borges; Danielle Queiroz Calcagno; Marília Cardoso Smith; Paulo Pimentel Assumpção; Rommel Rodríguez Burbano
Journal:  Clin Exp Med       Date:  2014-09-09       Impact factor: 3.984

6.  Alteration of p53 clonality accompanying colorectal cancer progression.

Authors:  A Kuwabara; H Watanabe; Y Ajioka; K Yasuda; H Saito; K Matsuda; H Kijima; K Hatakeyama
Journal:  Jpn J Cancer Res       Date:  1998-01

7.  Heterogeneity of p53 mutational status in intramucosal carcinoma of the colorectum.

Authors:  S Yamada; Y Ajioka; H Watanabe; H Hashidate; H Takaku; S Kazama; J Yokoyama; K Nishikura; T Fujiwara; H Asakura
Journal:  Jpn J Cancer Res       Date:  2001-02

8.  p53 and beta-catenin expression in gallbladder tissues and correlation with tumor progression in gallbladder cancer.

Authors:  Mila Ghosh; Puja Sakhuja; Shivendra Singh; Anil K Agarwal
Journal:  Saudi J Gastroenterol       Date:  2013 Jan-Feb       Impact factor: 2.485

9.  Mitotic count reflects prognosis of gallbladder cancer particularly among patients with T3 tumor.

Authors:  Keita Kai; Masanori Masuda; Takao Ide; Yukari Takase; Atsushi Miyoshi; Kenji Kitahara; Kohji Miyazaki; Hirokazu Noshiro; Osamu Tokunaga
Journal:  Mol Clin Oncol       Date:  2013-05-16

10.  Heterogeneity of p53 mutational status in esophageal squamous cell carcinoma.

Authors:  S Kuwabara; Y Ajioka; H Watanabe; J Hitomi; K Nishikura; K Hatakeyama
Journal:  Jpn J Cancer Res       Date:  1998-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.